K. Visvanathan, A. Cimino-Mathews, M. J. Fackler, et al., “Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk,” The Breast Journal 2022 (2022): 9533461, https://doi.org/10.1155/2022/9533461.
In the article titled “Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk,” there was an error in the Conflicts of Interest section. The corrected section appears below:
Conflicts of Interest
Kala Visvanathan reports funding from Cepheid and nonfinancial support from Optra Health Inc. Mary Jo Fackler reports grants from Cepheid and served as a Cepheid Consultant from February 2015 to February 2020. Mary Jo Fackler received license royalty fees from Cepheid from December 2014 through July 2021 for use of JHU cMethDNA and QM-MSP assays.
Saraswati Sukumar was awarded a grant from Cepheid and Kala Visvanathan and Mary Jo Fackler received support on it. Saraswati Sukumar served as Cepheid consultant from February 2015 through February 2020 and received license royalty fees from Cepheid (December 2014 through 2021) for use of JHU cMethDNA and QM-MSP patents. Mary Jo Fackler and Saraswati Sukumar are co-inventors of the cMethDNA assay, US patent US10450609B2. The JH Office of Policy is managing the COI for Saraswati Sukumar and Mary Jo Fackler. Vered Stearns received research grants to Johns Hopkins from Abbvie, Biocept, Novartis, Pfizer, Puma Biotechnology, and QUE. She served on the Oncology Advisory board for Novartis in 2021 and was Chair of a Data Safety Monitoring Board for AstraZeneca. She received nonfinancial support from Foundation Medicine for study assays.
We apologize for this error.
K. Visvanathan， A. ciminomathews， M. J. Fackler等，“评估随机乳腺细针抽吸器中的DNA甲基化以告知癌症风险”，《乳腺杂志》2022 (2022):9533461,https://doi.org/10.1155/2022/9533461.In文章标题为“评估随机乳腺细针抽吸器中的DNA甲基化以告知癌症风险”，在利益冲突部分有一个错误。更正后的部分如下：利益冲突kala Visvanathan报告了造父变星的资金和Optra Health Inc.的非财务支持。Mary Jo Fackler从2015年2月到2020年2月担任造父变星顾问。Mary Jo Fackler在2014年12月至2021年7月期间获得了仙王座JHU cMethDNA和QM-MSP检测的许可使用费。Saraswati Sukumar获得了造父变星的资助，Kala Visvanathan和Mary Jo Fackler也得到了支持。Saraswati Sukumar于2015年2月至2020年2月担任Cepheid顾问，并从Cepheid获得使用JHU cMethDNA和QM-MSP专利的许可使用费（2014年12月至2021年）。Mary Jo Fackler和Saraswati Sukumar是cMethDNA测定法的共同发明者，美国专利US10450609B2。JH政策办公室正在为Saraswati Sukumar和Mary Jo Fackler管理COI。从艾伯维、Biocept、诺华、辉瑞、彪马生物技术和QUE获得了约翰霍普金斯大学的研究资助。她于2021年担任Novartis肿瘤学顾问委员会成员，并担任AstraZeneca数据安全监测委员会主席。她的研究分析得到了基础医学的非经济支持。我们为这个错误道歉。
{"title":"Correction to “Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk”","authors":"","doi":"10.1155/tbj/9873020","DOIUrl":"https://doi.org/10.1155/tbj/9873020","url":null,"abstract":"<p>K. Visvanathan, A. Cimino-Mathews, M. J. Fackler, et al., “Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk,” <i>The Breast Journal</i> 2022 (2022): 9533461, https://doi.org/10.1155/2022/9533461.</p><p>In the article titled “Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk,” there was an error in the Conflicts of Interest section. The corrected section appears below:</p><p><b>Conflicts of Interest</b></p><p>Kala Visvanathan reports funding from Cepheid and nonfinancial support from Optra Health Inc. Mary Jo Fackler reports grants from Cepheid and served as a Cepheid Consultant from February 2015 to February 2020. Mary Jo Fackler received license royalty fees from Cepheid from December 2014 through July 2021 for use of JHU cMethDNA and QM-MSP assays.</p><p>Saraswati Sukumar was awarded a grant from Cepheid and Kala Visvanathan and Mary Jo Fackler received support on it. Saraswati Sukumar served as Cepheid consultant from February 2015 through February 2020 and received license royalty fees from Cepheid (December 2014 through 2021) for use of JHU cMethDNA and QM-MSP patents. Mary Jo Fackler and Saraswati Sukumar are co-inventors of the cMethDNA assay, US patent US10450609B2. The JH Office of Policy is managing the COI for Saraswati Sukumar and Mary Jo Fackler. Vered Stearns received research grants to Johns Hopkins from Abbvie, Biocept, Novartis, Pfizer, Puma Biotechnology, and QUE. She served on the Oncology Advisory board for Novartis in 2021 and was Chair of a Data Safety Monitoring Board for AstraZeneca. She received nonfinancial support from Foundation Medicine for study assays.</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9873020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145522078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zaida Morante, Yomali Ferreyra, Iris Otoya, Natalia Valdiviezo, Norma Huarcaya-Chombo, Gabriela Polo-Mendoza, Cindy Calle, Jessica Meza, Carlos Castañeda, Tatiana Vidaurre, Guillermo Valencia, Patricia Rioja, Hugo Fuentes, Silvia P. Neciosup, Henry L. Gomez
Background
Lack of human epidermal growth factor receptor 2 (HER2) expression limits targeted treatments for triple-negative breast cancer (TNBC). HER2 status changes after neoadjuvant chemotherapy (NAC) have been reported, but their impact on survival in Peruvian TNBC patients remains unexplored. Here, we aimed to assess HER2 status before and after NAC and its association with clinical characteristics, treatment response, and survival outcomes.
Methods
Our analysis included clinicopathological data from 159 TNBC patients diagnosed between 2015 and 2019 at the Instituto Nacional de Enfermedades Neoplásicas (Lima, Peru) who received NAC. Logistic regression was used to assess the association between HER2 status at diagnosis and pathological complete response (pCR). Cohen’s Kappa analysis evaluated the agreement between pre- and post-NAC HER2 status, while Kaplan–Meier analysis estimated the impact of HER2 changes on overall survival (OS) and disease-free survival (DFS)
Results
Among TNBC patients, 40.3% were HER2-low at diagnosis and 14.9% achieved pCR. Pretherapeutic HER2 status was not associated with pCR (OR = 1.4, 95% CI = 0.55–3.61, and p = 0.5). HER2 status remained unchanged in 62.8% of HER2-zero and 75.9% of HER2-low patients post-NAC, showing moderate concordance (Cohen’s kappa = 0.3418, p < 0.001). No significant OS improvements were observed in patients with HER2 transitions: HER2-zero/HER2-low (HR = 0.52, 95% CI = 0.22–1.24, and p = 0.14), HER2-low/HER2-zero (HR = 0.9, 95% CI = 0.34–2.40, and p = 0.8), or HER2-low/HER2-low (HR = 0.71, 95% CI = 0.34–1.49, and p = 0.4) compared with HER2-zero/HER2-zero. Similar findings were reported for DFS.
Conclusion
These findings suggest that HER2 status conversion may not be prognostic for patients with TNBC treated with neoadjuvant therapy.
人表皮生长因子受体2 （HER2）表达的缺乏限制了三阴性乳腺癌（TNBC）的靶向治疗。新辅助化疗（NAC）后HER2状态的改变已被报道，但其对秘鲁TNBC患者生存的影响仍未被探讨。在这里，我们旨在评估NAC前后的HER2状态及其与临床特征、治疗反应和生存结果的关系。方法：我们分析了2015年至2019年在秘鲁利马国立Enfermedades研究所Neoplásicas （Lima, Peru）诊断的159例接受NAC治疗的TNBC患者的临床病理数据。采用Logistic回归评估诊断时HER2状态与病理完全缓解（pCR）之间的关系。Cohen的Kappa分析评估了nac前和nac后HER2状态之间的一致性，Kaplan-Meier分析估计了HER2变化对总生存期（OS）和无病生存期（DFS）的影响。结果在TNBC患者中，40.3%在诊断时HER2低，14.9%达到pCR。治疗前HER2状态与pCR无关（OR = 1.4, 95% CI = 0.55-3.61, p = 0.5）。nac后，62.8%的HER2零和75.9%的HER2低患者的HER2状态保持不变，显示中度一致性（Cohen’s kappa = 0.3418, p < 0.001）。与HER2-zero/HER2-zero相比，HER2-zero/HER2-low （HR = 0.52, 95% CI = 0.22-1.24, p = 0.14）、HER2-low/HER2-zero （HR = 0.9, 95% CI = 0.34-2.40, p = 0.8）或HER2-low/HER2-low （HR = 0.71, 95% CI = 0.34-1.49, p = 0.4）患者的OS无显著改善。DFS也有类似的发现。结论这些发现提示HER2状态转换可能不是新辅助治疗TNBC患者的预后。
{"title":"Influence of HER2 Changes on Survival Outcomes After Neoadjuvant Chemotherapy in Peruvian Patients With Triple-Negative Breast Cancer","authors":"Zaida Morante, Yomali Ferreyra, Iris Otoya, Natalia Valdiviezo, Norma Huarcaya-Chombo, Gabriela Polo-Mendoza, Cindy Calle, Jessica Meza, Carlos Castañeda, Tatiana Vidaurre, Guillermo Valencia, Patricia Rioja, Hugo Fuentes, Silvia P. Neciosup, Henry L. Gomez","doi":"10.1155/tbj/3770655","DOIUrl":"https://doi.org/10.1155/tbj/3770655","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lack of human epidermal growth factor receptor 2 (HER2) expression limits targeted treatments for triple-negative breast cancer (TNBC). HER2 status changes after neoadjuvant chemotherapy (NAC) have been reported, but their impact on survival in Peruvian TNBC patients remains unexplored. Here, we aimed to assess HER2 status before and after NAC and its association with clinical characteristics, treatment response, and survival outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Our analysis included clinicopathological data from 159 TNBC patients diagnosed between 2015 and 2019 at the Instituto Nacional de Enfermedades Neoplásicas (Lima, Peru) who received NAC. Logistic regression was used to assess the association between HER2 status at diagnosis and pathological complete response (pCR). Cohen’s Kappa analysis evaluated the agreement between pre- and post-NAC HER2 status, while Kaplan–Meier analysis estimated the impact of HER2 changes on overall survival (OS) and disease-free survival (DFS)</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among TNBC patients, 40.3% were HER2-low at diagnosis and 14.9% achieved pCR. Pretherapeutic HER2 status was not associated with pCR (OR = 1.4, 95% CI = 0.55–3.61, and <i>p</i> = 0.5). HER2 status remained unchanged in 62.8% of HER2-zero and 75.9% of HER2-low patients post-NAC, showing moderate concordance (Cohen’s kappa = 0.3418, <i>p</i> < 0.001). No significant OS improvements were observed in patients with HER2 transitions: HER2-zero/HER2-low (HR = 0.52, 95% CI = 0.22–1.24, and <i>p</i> = 0.14), HER2-low/HER2-zero (HR = 0.9, 95% CI = 0.34–2.40, and <i>p</i> = 0.8), or HER2-low/HER2-low (HR = 0.71, 95% CI = 0.34–1.49, and <i>p</i> = 0.4) compared with HER2-zero/HER2-zero. Similar findings were reported for DFS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that HER2 status conversion may not be prognostic for patients with TNBC treated with neoadjuvant therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/3770655","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145522313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica C. Gooch, Qi Ying McClelland, Kathryn Paschalis, Maya Anand, Allison Magnuson, Jenna Dobbins, Kristin A. Skinner, Ann Olzinski-Kunze, Anna Weiss
Background
The safety and value of same-day mastectomy are well-documented but the patient perspective is underreported, especially among older patients. This study aimed to investigate older patient-reported recovery quality after mastectomy; we hypothesized that patients who were discharged same day would report better recovery.
Methods
A prospective trial included frailty screening and prehabilitation for patients age ≥ 65 undergoing mastectomy for breast cancer. Primary endpoint, same-day discharge rate, was previously reported and was significantly higher than the year prior. Secondary endpoint was patient-reported postoperative recovery quality, per the Quality of Recovery-15 measure (QoR-15; 15 questions scored 1–10, 10 being best). Patients responded by phone 24–72 h postdischarge. One-tailed T-tests compared responses between same-day and admitted patients.
Results
37/55 (67.3%) patients ≥ 65 who underwent unilateral/bilateral mastectomy for early-stage breast cancer responded. Mean age was 73.6 (standard deviation 7.6), most had invasive carcinoma (44, 80.0%), and mean 5-factor Modified Frailty Index (mFI-5) was 1.3 of 5 (standard deviation 0.9); nonresponders had similar characteristics. There were no significant differences in any QoR-15 item (all p > 0.05). In fact, most responses were very similar, different by only one-tenth of 1 point or identical. The following answers slightly (0.2 difference or more) numerically favored same-day discharge: feeling rested, having good sleep, less moderate pain, and freedom from feeling anxious or depressed. No items favored admission.
Conclusions
Although this trial was not powered for secondary analyses, it is clinically meaningful that older patients undergoing same-day mastectomy reported similar recovery quality as those admitted. Same-day mastectomy should be considered for older patients.
{"title":"Patient-Reported Outcomes After Same-Day Mastectomy Among Older Breast Cancer Patients: Results From a Prospective Clinical Trial","authors":"Jessica C. Gooch, Qi Ying McClelland, Kathryn Paschalis, Maya Anand, Allison Magnuson, Jenna Dobbins, Kristin A. Skinner, Ann Olzinski-Kunze, Anna Weiss","doi":"10.1155/tbj/9953747","DOIUrl":"https://doi.org/10.1155/tbj/9953747","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The safety and value of same-day mastectomy are well-documented but the patient perspective is underreported, especially among older patients. This study aimed to investigate older patient-reported recovery quality after mastectomy; we hypothesized that patients who were discharged same day would report better recovery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective trial included frailty screening and prehabilitation for patients age ≥ 65 undergoing mastectomy for breast cancer. Primary endpoint, same-day discharge rate, was previously reported and was significantly higher than the year prior. Secondary endpoint was patient-reported postoperative recovery quality, per the Quality of Recovery-15 measure (QoR-15; 15 questions scored 1–10, 10 being best). Patients responded by phone 24–72 h postdischarge. One-tailed <i>T</i>-tests compared responses between same-day and admitted patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>37/55 (67.3%) patients ≥ 65 who underwent unilateral/bilateral mastectomy for early-stage breast cancer responded. Mean age was 73.6 (standard deviation 7.6), most had invasive carcinoma (44, 80.0%), and mean 5-factor Modified Frailty Index (mFI-5) was 1.3 of 5 (standard deviation 0.9); nonresponders had similar characteristics. There were no significant differences in any QoR-15 item (all <i>p</i> > 0.05). In fact, most responses were very similar, different by only one-tenth of 1 point or identical. The following answers slightly (0.2 difference or more) numerically favored same-day discharge: feeling rested, having good sleep, less moderate pain, and freedom from feeling anxious or depressed. No items favored admission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although this trial was not powered for secondary analyses, it is clinically meaningful that older patients undergoing same-day mastectomy reported similar recovery quality as those admitted. Same-day mastectomy should be considered for older patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9953747","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145470049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junyue Wang, Dongxiao Zhang, Qiao Huang, Na Fu, Wenjie Zhao, Yu Zhou, Yubo Guo, Xiaolong Xu, Yudong Li
Background
While the characteristics of pathologic nipple discharge (PND) are well documented in the literature, comparative clinical and risk factor analyses across different pathologic subtypes are lacking.
Methods
Medical records of patients with nipple discharge were retrospectively retrieved from an electronic medical record database and analyzed. In this study, 375 patients with a postoperative pathologically confirmed diagnosis of PND were included.
Results
Age serves as an important independent risk factor for precancerous lesions and breast cancer, with the median age increasing alongside the severity of the pathology. Individuals under 45 years of age predominantly exhibited non-neoplastic and benign neoplastic lesions, whereas those over 45 were more likely to have precancerous lesions or breast cancer, with statistical significance (p < 0.01). Discharge color was a significant factor in distinguishing between different pathological findings (p < 0.01). Discharge color serves as an important independent risk factor for breast cancer. Bloody discharge was associated with a significantly higher incidence of breast cancer and precancerous lesions compared to non-bloody discharges. Upon dividing bloody discharge into brown and bright red for in-depth analysis, no significant difference was observed among the different pathological types (p > 0.05). Ductoscopy has a higher diagnostic rate for breast cancer and precancerous lesions (p < 0.01).
Conclusion
These results suggest the clinical characteristics of PND patients across four pathological types: non-neoplastic lesions, benign neoplastic lesions, precancerous lesions, and breast cancer, at the same time emphasizing the importance of age and discharge color as independent risk factors in the prognosis and management of nipple discharge.
{"title":"Clinical Characteristics and Independent Risk Factors for Pathologic Nipple Discharge of 375 Cases","authors":"Junyue Wang, Dongxiao Zhang, Qiao Huang, Na Fu, Wenjie Zhao, Yu Zhou, Yubo Guo, Xiaolong Xu, Yudong Li","doi":"10.1155/tbj/6615296","DOIUrl":"https://doi.org/10.1155/tbj/6615296","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While the characteristics of pathologic nipple discharge (PND) are well documented in the literature, comparative clinical and risk factor analyses across different pathologic subtypes are lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Medical records of patients with nipple discharge were retrospectively retrieved from an electronic medical record database and analyzed. In this study, 375 patients with a postoperative pathologically confirmed diagnosis of PND were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Age serves as an important independent risk factor for precancerous lesions and breast cancer, with the median age increasing alongside the severity of the pathology. Individuals under 45 years of age predominantly exhibited non-neoplastic and benign neoplastic lesions, whereas those over 45 were more likely to have precancerous lesions or breast cancer, with statistical significance (<i>p</i> < 0.01). Discharge color was a significant factor in distinguishing between different pathological findings (<i>p</i> < 0.01). Discharge color serves as an important independent risk factor for breast cancer. Bloody discharge was associated with a significantly higher incidence of breast cancer and precancerous lesions compared to non-bloody discharges. Upon dividing bloody discharge into brown and bright red for in-depth analysis, no significant difference was observed among the different pathological types (<i>p</i> > 0.05). Ductoscopy has a higher diagnostic rate for breast cancer and precancerous lesions (<i>p</i> < 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These results suggest the clinical characteristics of PND patients across four pathological types: non-neoplastic lesions, benign neoplastic lesions, precancerous lesions, and breast cancer, at the same time emphasizing the importance of age and discharge color as independent risk factors in the prognosis and management of nipple discharge.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6615296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145406903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kewei Tang, Site Bai, Qiang Zhou, Songlian Liu, Leilan Yin, Yajun Tong, Ling Long, Ludi Ou, Qinghua Yin
Objective
To investigate the effect of microRNA-195-5p (miRNA-195-5p) on proliferation and malignant metastasis in triple-negative breast cancer (TNBC) cells and its underlying mechanism.
Methods
Expression levels of miRNA-195-5p and MYB were determined by quantitative real-time PCR (RT-qPCR) in TNBC cells (MDA-MB-231 and BT-549) and normal human mammary epithelial cells (MCF-10A). Cell proliferation was assessed via CCK-8 assays after miRNA-195-5p overexpression or knockdown in MDA-MB-231 cells. Transwell assays evaluated cellular invasion and migration. Western blotting analyzed impacts on the PI3K/AKT/mTOR pathway. Targeting of MYB by miRNA-195-5p was confirmed using TargetScan prediction and dual-luciferase reporter assays. RT-qPCR measured MYB expression upon miRNA-195-5p modulation. Rescue experiments (co-overexpression of MYB and miRNA-195-5p) further assessed proliferation and PI3K/AKT/mTOR signaling via CCK-8 and Western blotting.
Results
Compared to MCF-10A cells, miRNA-195-5p expression was significantly downregulated (p < 0.01), while MYB was markedly upregulated (p < 0.001) in TNBC cells. Overexpression of miRNA-195-5p inhibited MDA-MB-231 proliferation, invasion, and migration; conversely, its knockdown promoted these phenotypes. MiRNA-195-5p directly targeted and negatively regulated MYB. MYB overexpression activated the PI3K/AKT/mTOR pathway, enhancing cell proliferation. Rescue experiments indicated that MYB upregulation counteracted the tumor-suppressive effects of miRNA-195-5p and reactivated PI3K/AKT/mTOR signaling.
Conclusion
miRNA-195-5p suppresses proliferation and metastasis in TNBC by targeting MYB and inhibiting the PI3K/AKT/mTOR pathway.
{"title":"MicroRNA-195-5p Targets MYB to Regulate Proliferation and Malignant Metastasis in Triple-Negative Breast Cancer via PI3K/AKT/mTOR Signaling","authors":"Kewei Tang, Site Bai, Qiang Zhou, Songlian Liu, Leilan Yin, Yajun Tong, Ling Long, Ludi Ou, Qinghua Yin","doi":"10.1155/tbj/7303173","DOIUrl":"https://doi.org/10.1155/tbj/7303173","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the effect of microRNA-195-5p (miRNA-195-5p) on proliferation and malignant metastasis in triple-negative breast cancer (TNBC) cells and its underlying mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Expression levels of miRNA-195-5p and MYB were determined by quantitative real-time PCR (RT-qPCR) in TNBC cells (MDA-MB-231 and BT-549) and normal human mammary epithelial cells (MCF-10A). Cell proliferation was assessed via CCK-8 assays after miRNA-195-5p overexpression or knockdown in MDA-MB-231 cells. Transwell assays evaluated cellular invasion and migration. Western blotting analyzed impacts on the PI3K/AKT/mTOR pathway. Targeting of MYB by miRNA-195-5p was confirmed using TargetScan prediction and dual-luciferase reporter assays. RT-qPCR measured MYB expression upon miRNA-195-5p modulation. Rescue experiments (co-overexpression of MYB and miRNA-195-5p) further assessed proliferation and PI3K/AKT/mTOR signaling via CCK-8 and Western blotting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to MCF-10A cells, miRNA-195-5p expression was significantly downregulated (<i>p</i> < 0.01), while MYB was markedly upregulated (<i>p</i> < 0.001) in TNBC cells. Overexpression of miRNA-195-5p inhibited MDA-MB-231 proliferation, invasion, and migration; conversely, its knockdown promoted these phenotypes. MiRNA-195-5p directly targeted and negatively regulated MYB. MYB overexpression activated the PI3K/AKT/mTOR pathway, enhancing cell proliferation. Rescue experiments indicated that MYB upregulation counteracted the tumor-suppressive effects of miRNA-195-5p and reactivated PI3K/AKT/mTOR signaling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>miRNA-195-5p suppresses proliferation and metastasis in TNBC by targeting MYB and inhibiting the PI3K/AKT/mTOR pathway.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7303173","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Flemming Puscz, Nilofar Ahmadi, Sonja Verena Schmidt, Felix Reinkemeier, Marius Drysch, Yonca Steubing, Maximilian Völlmecke, Marcus Lehnhardt, Christoph Wallner
Background
Angiosarcomas (ASs) are a heterogeneous subtype of soft tissue sarcomas. They can be subdivided into primary and secondary AS, with secondary AS being predominant, particularly those following radiotherapy. The aim of this study was first to analyze our patient cohort on a descriptive level and then to identify possible risk factors with regard to one and 5-year survival using logistic regression.
Methods
The study was designed as a retrospective, single-center cohort study. All patients with histologically confirmed AS over 18 years of age were included in the study. Binary logistic regression was used for univariate analysis screening of continuous or dichotomous variables, respectively. For multivariate analysis, binary multivariate logistic regression was performed to assess independent associations between chosen variables and AS.
Results
A total of 39 patients were included in this study. 14 (35.9%) had primary and 25 (64%) had secondary AS. Women were more frequently affected (76.9%) than men (23.1%). The 1-year survival rate was 87.2%, and the 5-year survival rate was 51.3%. In the logistic regression analyses, nicotine consumption and a history of carcinoma were identified as significant factors influencing the 1-year survival rate. For the 5-year survival rate, only breast cancer was found to be a significant influencing factor in the univariate analysis. Based on univariate logistic regression, all variables with a p value of < 0.1 were chosen to be included into multivariate analysis. The multivariate analysis showed diabetes mellitus (p = 0.067) with an association to influence the 5-year survival rate.
Conclusions
We were able to show that the proportion of secondary ASs is predominant. These occur after radiation treatment of the breast. Diabetes mellitus may be associated with reduced 5-year survival, although this finding did not reach statistical significance and requires further investigation. Due to its small sample size, this study should be regarded more as hypothesis-generating.
{"title":"Characteristics, Outcomes, and Risk Factors in Primary and Secondary Angiosarcoma: A Retrospective Cohort Study","authors":"Flemming Puscz, Nilofar Ahmadi, Sonja Verena Schmidt, Felix Reinkemeier, Marius Drysch, Yonca Steubing, Maximilian Völlmecke, Marcus Lehnhardt, Christoph Wallner","doi":"10.1155/tbj/7158762","DOIUrl":"https://doi.org/10.1155/tbj/7158762","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Angiosarcomas (ASs) are a heterogeneous subtype of soft tissue sarcomas. They can be subdivided into primary and secondary AS, with secondary AS being predominant, particularly those following radiotherapy. The aim of this study was first to analyze our patient cohort on a descriptive level and then to identify possible risk factors with regard to one and 5-year survival using logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study was designed as a retrospective, single-center cohort study. All patients with histologically confirmed AS over 18 years of age were included in the study. Binary logistic regression was used for univariate analysis screening of continuous or dichotomous variables, respectively. For multivariate analysis, binary multivariate logistic regression was performed to assess independent associations between chosen variables and AS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 39 patients were included in this study. 14 (35.9%) had primary and 25 (64%) had secondary AS. Women were more frequently affected (76.9%) than men (23.1%). The 1-year survival rate was 87.2%, and the 5-year survival rate was 51.3%. In the logistic regression analyses, nicotine consumption and a history of carcinoma were identified as significant factors influencing the 1-year survival rate. For the 5-year survival rate, only breast cancer was found to be a significant influencing factor in the univariate analysis. Based on univariate logistic regression, all variables with a <i>p</i> value of < 0.1 were chosen to be included into multivariate analysis. The multivariate analysis showed diabetes mellitus (<i>p</i> = 0.067) with an association to influence the 5-year survival rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We were able to show that the proportion of secondary ASs is predominant. These occur after radiation treatment of the breast. Diabetes mellitus may be associated with reduced 5-year survival, although this finding did not reach statistical significance and requires further investigation. Due to its small sample size, this study should be regarded more as hypothesis-generating.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7158762","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas J. Sorenson, Carter J. Boyd, Jenn J. Park, Kshipra Hemal, Chris Amro, Nicholas Vernice, Alexis Lakatta, Oriana Cohen, Nolan Karp, Mihye Choi
Background
Nipple-sparing mastectomy (NSM) with implant-based breast reconstruction (IBBR) preserves the nipple-areolar complex (NAC) with superior aesthetic results but results in loss of nipple sensation. Nipple neurotization has emerged as a technique to restore the sensory function, yet outcomes remain variable across studies. This systematic review synthesizes the available evidence on nipple neurotization in IBBR, focusing on sensory recovery, patient satisfaction, and surgical techniques.
Methods
A systematic review was conducted following PRISMA guidelines. PubMed, Ovid EMBASE, and Cochrane Library were searched through April 1, 2025, for studies evaluating nipple neurotization in IBBR. Eligible studies included randomized controlled trials, cohort studies, and case series reporting surgical technique, sensory, and/or patient satisfaction outcomes. Data extraction included study characteristics, surgical techniques, sensory outcomes, and patient-reported satisfaction. Risk of bias was assessed using standardized tools.
Results
Six studies met inclusion criteria, comprising 212 patients and 257 neurotized breasts. Sensory recovery was assessed using monofilament testing and patient-reported outcomes. Studies demonstrated overall improvement of NAC sensory outcomes and high patient satisfaction after neurotization. However, variability in neurotization methods, follow-up duration, and specific measured sensory outcomes limited direct comparisons.
Conclusion
Nipple neurotization in IBBR shows promise in enhancing sensory recovery and patient satisfaction after NSM, but heterogeneity in surgical techniques and outcome measures, as well as poor study designs, limits definitive conclusions. Standardized protocols and randomized studies with long-term patient follow-up are needed to establish best practices and optimize neurotization outcomes.
{"title":"Nipple Areolar Complex (NAC) Neurotization After Nipple-Sparing Mastectomy (NSM) in Implant-Based Breast Reconstruction: A Systematic Review of the Literature","authors":"Thomas J. Sorenson, Carter J. Boyd, Jenn J. Park, Kshipra Hemal, Chris Amro, Nicholas Vernice, Alexis Lakatta, Oriana Cohen, Nolan Karp, Mihye Choi","doi":"10.1155/tbj/2362697","DOIUrl":"https://doi.org/10.1155/tbj/2362697","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nipple-sparing mastectomy (NSM) with implant-based breast reconstruction (IBBR) preserves the nipple-areolar complex (NAC) with superior aesthetic results but results in loss of nipple sensation. Nipple neurotization has emerged as a technique to restore the sensory function, yet outcomes remain variable across studies. This systematic review synthesizes the available evidence on nipple neurotization in IBBR, focusing on sensory recovery, patient satisfaction, and surgical techniques.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review was conducted following PRISMA guidelines. PubMed, Ovid EMBASE, and Cochrane Library were searched through April 1, 2025, for studies evaluating nipple neurotization in IBBR. Eligible studies included randomized controlled trials, cohort studies, and case series reporting surgical technique, sensory, and/or patient satisfaction outcomes. Data extraction included study characteristics, surgical techniques, sensory outcomes, and patient-reported satisfaction. Risk of bias was assessed using standardized tools.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Six studies met inclusion criteria, comprising 212 patients and 257 neurotized breasts. Sensory recovery was assessed using monofilament testing and patient-reported outcomes. Studies demonstrated overall improvement of NAC sensory outcomes and high patient satisfaction after neurotization. However, variability in neurotization methods, follow-up duration, and specific measured sensory outcomes limited direct comparisons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Nipple neurotization in IBBR shows promise in enhancing sensory recovery and patient satisfaction after NSM, but heterogeneity in surgical techniques and outcome measures, as well as poor study designs, limits definitive conclusions. Standardized protocols and randomized studies with long-term patient follow-up are needed to establish best practices and optimize neurotization outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/2362697","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atif Ali Hashmi, Noreen Wahid, Ghazala Mudassir, Muhammad Irfan, Umair Arshad Malik, Erum Yousuf Khan, Syed Muhammad Abu Bakar, Naveen Faridi
<div> <section> <h3> Background</h3> <p>Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple-negative breast cancer (TNBC), there is a lack of PDL1 expression data in Pakistani breast cancer patients. In our study, PDL1 expression was assessed in TNBC to determine eligibility for PDL1 inhibitors. Our study aimed to evaluate the frequency of PDL1 expression in TNBC. We also examined how PDL1 expression correlates with clinicopathological characteristics and prognostic factors in patients with TNBC. Moreover, the association of neoadjuvant chemotherapy response with PDL1 expression was also evaluated.</p> </section> <section> <h3> Methods</h3> <p>This cross-sectional study was conducted at the Liaquat National Hospital Histopathology Department from January 2022 to June 2023. A total of 128 biopsy-proven cases of TNBCs were administered neoadjuvant chemotherapy before surgery during this period. PDL1 immunohistochemical staining was performed on prechemotherapy needle biopsies. Expression was determined using the combined positive score (CPS). CPS is the number of PDL1-stained cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. Cases with CPS ≥ 10 were considered PDL1-positive.</p> </section> <section> <h3> Results</h3> <p>Complete pathological response (pCR) was observed in 32.8% (<i>n</i> = 42) of cases. PDL1 expression was observed in 18.8% (<i>n</i> = 24) of cases. The majority of cases showed a high residual cancer burden (RCB-III) (<i>n</i> = 53, 41.4%). A significant association was noted between PDL1 expression and neoadjuvant chemotherapy response (<i>p</i> < 0.01). PDL1-positive cases had a higher pCR (<i>n</i> = 16, 66.7%) than PDL1-negative cases (<i>n</i> = 26, 25%). PDL1-positive cases showed a lower frequency of RCB-II-III (RCB-II: 8.3%; RCB-III: 0%) than PDL1-negative cases (RCB-II: 25%; RCB-III: 51%), with a significant <i>p</i> value (<i>p</i> < 0.01).</p> </section> <section> <h3> Conclusion</h3> <p>Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we reco
{"title":"Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden","authors":"Atif Ali Hashmi, Noreen Wahid, Ghazala Mudassir, Muhammad Irfan, Umair Arshad Malik, Erum Yousuf Khan, Syed Muhammad Abu Bakar, Naveen Faridi","doi":"10.1155/tbj/8856567","DOIUrl":"https://doi.org/10.1155/tbj/8856567","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple-negative breast cancer (TNBC), there is a lack of PDL1 expression data in Pakistani breast cancer patients. In our study, PDL1 expression was assessed in TNBC to determine eligibility for PDL1 inhibitors. Our study aimed to evaluate the frequency of PDL1 expression in TNBC. We also examined how PDL1 expression correlates with clinicopathological characteristics and prognostic factors in patients with TNBC. Moreover, the association of neoadjuvant chemotherapy response with PDL1 expression was also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study was conducted at the Liaquat National Hospital Histopathology Department from January 2022 to June 2023. A total of 128 biopsy-proven cases of TNBCs were administered neoadjuvant chemotherapy before surgery during this period. PDL1 immunohistochemical staining was performed on prechemotherapy needle biopsies. Expression was determined using the combined positive score (CPS). CPS is the number of PDL1-stained cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. Cases with CPS ≥ 10 were considered PDL1-positive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Complete pathological response (pCR) was observed in 32.8% (<i>n</i> = 42) of cases. PDL1 expression was observed in 18.8% (<i>n</i> = 24) of cases. The majority of cases showed a high residual cancer burden (RCB-III) (<i>n</i> = 53, 41.4%). A significant association was noted between PDL1 expression and neoadjuvant chemotherapy response (<i>p</i> < 0.01). PDL1-positive cases had a higher pCR (<i>n</i> = 16, 66.7%) than PDL1-negative cases (<i>n</i> = 26, 25%). PDL1-positive cases showed a lower frequency of RCB-II-III (RCB-II: 8.3%; RCB-III: 0%) than PDL1-negative cases (RCB-II: 25%; RCB-III: 51%), with a significant <i>p</i> value (<i>p</i> < 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we reco","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/8856567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicole Nelson, Jennifer Den, Roi Weiser, Biai Digbeu, H. Colleen Silva, Angelica S. Robinson, Flavia Poselman, V. Suzanne Klimberg
Background: Clips placed after core needle biopsy are often several millimeters to centimeters from the biopsy cavity. Radiofrequency and radar (R) localization involve a second localization procedure based on the prior clip placement, potentially compounding the distance from the area localized to the original biopsy site. Fluoroscopic intraoperative neoplasm detection (FIND) obviates the need for a second localization by using intraoperative fluoroscopy to localize the original biopsy clip. We hypothesized that intraoperative localization using FIND is feasible and may result in fewer positive margins.
Methods: A retrospective review was performed of patients with nonpalpable malignancy who underwent partial mastectomy from September 2016 to August 2023. Results were compared between patients who underwent R localization vs. FIND. The Pythagorean theorem was used to calculate the distance in space between the biopsy clip and the R localization device. Chi-square was used to calculate the two-tailed p value.
Results: We identified 219 patients: 161 localized with FIND and 55 with R. Three percent (6 out of 161) of the patients with FIND and 12% (7 out of 55) of the patients with R had positive margins (p = 0.01). The average distance between the R device and biopsy clip in patients with positive margins was 19.1 mm, and with negative margins, it was 12.45 mm (p = 0.09).
Conclusions: The positive margin rate with R localization was significantly greater than with FIND. The positive margin rate trended toward increased distance from the localization device to the biopsy clip. Eliminating the second localization decreases painful procedures for the patient and may result in improved tumor-free margins.
背景：芯针活检后放置的夹子通常距离活检腔几毫米到几厘米。射频和雷达(R)定位涉及基于先前夹子放置的第二次定位程序，可能会增加从定位区域到原始活检部位的距离。术中透视肿瘤检测（FIND）通过使用术中透视来定位原始活检夹，从而避免了第二次定位的需要。我们假设术中使用FIND定位是可行的，并且导致较少的阳性切缘。方法：回顾性分析2016年9月至2023年8月行乳房部分切除术的不可触及恶性肿瘤患者。结果比较了进行R定位和FIND的患者。使用勾股定理计算活检夹与R定位装置之间的空间距离。采用卡方法计算双侧p值。结果：我们确定了219例患者：161例局限性FIND和55例R。3%（161例中有6例）的FIND患者和12%（55例中有7例）的R患者边缘呈阳性（p = 0.01）。切缘阳性患者R装置与活检夹的平均距离为19.1 mm，切缘阴性患者R装置与活检夹的平均距离为12.45 mm （p = 0.09）。结论：R定位的阳性切缘率明显高于FIND。阳性切缘率倾向于从定位装置到活检夹的距离增加。消除第二次定位减少了患者的痛苦过程，并可能导致改善的无肿瘤边缘。
{"title":"The Era “or Error” of Second Localization Procedures","authors":"Nicole Nelson, Jennifer Den, Roi Weiser, Biai Digbeu, H. Colleen Silva, Angelica S. Robinson, Flavia Poselman, V. Suzanne Klimberg","doi":"10.1155/tbj/6391905","DOIUrl":"https://doi.org/10.1155/tbj/6391905","url":null,"abstract":"<p><b>Background:</b> Clips placed after core needle biopsy are often several millimeters to centimeters from the biopsy cavity. Radiofrequency and radar (R) localization involve a second localization procedure based on the prior clip placement, potentially compounding the distance from the area localized to the original biopsy site. Fluoroscopic intraoperative neoplasm detection (FIND) obviates the need for a second localization by using intraoperative fluoroscopy to localize the original biopsy clip. We hypothesized that intraoperative localization using FIND is feasible and may result in fewer positive margins.</p><p><b>Methods:</b> A retrospective review was performed of patients with nonpalpable malignancy who underwent partial mastectomy from September 2016 to August 2023. Results were compared between patients who underwent R localization vs. FIND. The Pythagorean theorem was used to calculate the distance in space between the biopsy clip and the R localization device. Chi-square was used to calculate the two-tailed <i>p</i> value.</p><p><b>Results:</b> We identified 219 patients: 161 localized with FIND and 55 with R. Three percent (6 out of 161) of the patients with FIND and 12% (7 out of 55) of the patients with R had positive margins (<i>p</i> = 0.01). The average distance between the R device and biopsy clip in patients with positive margins was 19.1 mm, and with negative margins, it was 12.45 mm (<i>p</i> = 0.09).</p><p><b>Conclusions:</b> The positive margin rate with R localization was significantly greater than with FIND. The positive margin rate trended toward increased distance from the localization device to the biopsy clip. Eliminating the second localization decreases painful procedures for the patient and may result in improved tumor-free margins.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6391905","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast cancer survivors. However, a qualitative perspective is essential to create appropriate adaptations for this population. This study aims to develop a deeper understanding of the experiences of female adult breast cancer survivors with physical activity in their postdiagnosis lifestyle.
Methods: This study followed a qualitative systematic review methodology. In January 2024, six databases (APA PsycInfo, CINAHL Plus, OVID Medline, Scopus, SPORTDiscus and Sports Medicine an Education Index) were searched using aim-specific key terms. Ten studies, comprising a total sample of 200 participants, met the inclusion criteria. Quality appraisal, data extraction and synthesis stages were conducted.
Results: Five main themes emerged during the synthesis stage: (1) Outcomes of Physical Activity Participation, (2) Barriers to Physical Activity, (3) Postdiagnosis Balancing Act, (4) Needs for Future Physical Activity Programs and (5) Next Steps for Breast Cancer Survivors. Additionally, 15 subthemes were identified.
Conclusion: Overall, breast cancer survivors reported positive experiences with physical activity, leading to a desire to maintain an active lifestyle. However, barriers such as treatment side effects, unmet needs for advice from health services and challenges in daily life postdiagnosis were identified. Future research should explore the implementation of specific national guidelines and recommendations for survivors postdiagnosis to overcome these barriers and enhance the quality of survivorship care.
背景：随着乳腺癌存活率的增加，有必要进行更多的研究来了解幸存者的经历。之前的定量研究表明，体育锻炼对乳腺癌幸存者有益。但是，要为这一群体创造适当的适应条件，必须从质量角度出发。本研究旨在更深入地了解成年女性乳腺癌幸存者在诊断后的生活方式中进行体育锻炼的经历。方法：本研究采用定性系统评价方法。在2024年1月，我们使用目标特定的关键词检索了六个数据库（APA PsycInfo、CINAHL Plus、OVID Medline、Scopus、SPORTDiscus和Sports Medicine an Education Index）。10项研究，包括200名参与者的总样本，符合纳入标准。质量评价、数据提取和综合阶段。结果：在综合阶段出现了五个主要主题：(1)体育活动参与的结果；(2)体育活动的障碍；(3)诊断后平衡行为；(4)未来体育活动计划的需求；(5)乳腺癌幸存者的下一步。此外，确定了15个次级主题。结论：总体而言，乳腺癌幸存者报告了积极的体育锻炼经历，导致他们希望保持积极的生活方式。然而，也发现了一些障碍，如治疗副作用、保健服务咨询需求未得到满足以及诊断后日常生活中的挑战。未来的研究应探索实施具体的国家指南和建议，为幸存者诊断后克服这些障碍，提高生存护理的质量。
{"title":"Life Postdiagnosis: Female Adult Breast Cancer Survivors’ Experience With Physical Activity—A Qualitative Systematic Review","authors":"Neeve Brown, Fiona Muirhead","doi":"10.1155/tbj/6926093","DOIUrl":"https://doi.org/10.1155/tbj/6926093","url":null,"abstract":"<p><b>Background:</b> With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast cancer survivors. However, a qualitative perspective is essential to create appropriate adaptations for this population. This study aims to develop a deeper understanding of the experiences of female adult breast cancer survivors with physical activity in their postdiagnosis lifestyle.</p><p><b>Methods:</b> This study followed a qualitative systematic review methodology. In January 2024, six databases (APA PsycInfo, CINAHL Plus, OVID Medline, Scopus, SPORTDiscus and Sports Medicine an Education Index) were searched using aim-specific key terms. Ten studies, comprising a total sample of 200 participants, met the inclusion criteria. Quality appraisal, data extraction and synthesis stages were conducted.</p><p><b>Results:</b> Five main themes emerged during the synthesis stage: (1) Outcomes of Physical Activity Participation, (2) Barriers to Physical Activity, (3) Postdiagnosis Balancing Act, (4) Needs for Future Physical Activity Programs and (5) Next Steps for Breast Cancer Survivors. Additionally, 15 subthemes were identified.</p><p><b>Conclusion:</b> Overall, breast cancer survivors reported positive experiences with physical activity, leading to a desire to maintain an active lifestyle. However, barriers such as treatment side effects, unmet needs for advice from health services and challenges in daily life postdiagnosis were identified. Future research should explore the implementation of specific national guidelines and recommendations for survivors postdiagnosis to overcome these barriers and enhance the quality of survivorship care.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6926093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号